Mark S. Dennis

Denali Therapeutics (United States) — United States

Medicine · Health Sciences

52h-index11.1kcitations141works20.92yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Monoclonal and Polyclonal Antibodies Research(53), Glycosylation and Glycoproteins Research(16), HER2/EGFR in Cancer Research(12), CAR-T cell therapy research(12), Blood Coagulation and Thrombosis Mechanisms(11)

Publications141 total

Transferrin receptor–targeted anti-amyloid antibody enhances brain delivery and mitigates ARIA
Science·2025· 25 cited
Dual targeting of transferrin receptor and CD98hc enhances brain exposure of large molecules
Cell Reports·2025· 6 citedOpen Access
KU124 (9,10,10-trioxo-N-(2-phenylphenyl)thioxanthene-3-carboxamide) as a novel inhibitor of TASK-1
Frontiers in Pharmacology·2025Open Access
Dual targeting of transferrin receptor and CD98hc enhances brain exposure of large molecules
2025· 2 citedOpen Access
Targeting the transferrin receptor to transport antisense oligonucleotides across the mammalian blood-brain barrier
Science Translational Medicine·2024· 94 cited
Engineering anti-amyloid antibodies with transferrin receptor targeting improves brain biodistribution and mitigates ARIA
2024· 13 citedOpen Access
Rescue of a lysosomal storage disorder caused by Grn loss of function with a brain penetrant progranulin biologic
Cell·2024· 6 citedOpen Access
Author Correction: CD98hc is a target for brain delivery of biotherapeutics
Nature Communications·2023· 2 citedOpen Access
CD98hc is a target for brain delivery of biotherapeutics
Nature Communications·2023· 77 citedOpen Access
Targeting Transferrin Receptor to Transport Antisense Oligonucleotides Across the Blood-Brain Barrier
2023· 24 citedOpen Access
Supplementary Table 2 from An Antimesothelin-Monomethyl Auristatin E Conjugate with Potent Antitumor Activity in Ovarian, Pancreatic, and Mesothelioma Models
2023Open Access
Data from An Anti-GDNF Family Receptor Alpha 1 (GFRA1) Antibody–Drug Conjugate for the Treatment of Hormone Receptor–Positive Breast Cancer
2023Open Access
Supplementary Figure 2 from An Antimesothelin-Monomethyl Auristatin E Conjugate with Potent Antitumor Activity in Ovarian, Pancreatic, and Mesothelioma Models
2023Open Access
Figures S1-S4, Tables S1-S2 from An Anti-GDNF Family Receptor Alpha 1 (GFRA1) Antibody–Drug Conjugate for the Treatment of Hormone Receptor–Positive Breast Cancer
2023Open Access
Data from An Antimesothelin-Monomethyl Auristatin E Conjugate with Potent Antitumor Activity in Ovarian, Pancreatic, and Mesothelioma Models
2023Open Access
Supplementary Figure 2 from An Antimesothelin-Monomethyl Auristatin E Conjugate with Potent Antitumor Activity in Ovarian, Pancreatic, and Mesothelioma Models
2023Open Access
Supplementary Table 1 from An Antimesothelin-Monomethyl Auristatin E Conjugate with Potent Antitumor Activity in Ovarian, Pancreatic, and Mesothelioma Models
2023Open Access
Data from Relative Target Affinities of T-Cell–Dependent Bispecific Antibodies Determine Biodistribution in a Solid Tumor Mouse Model
2023Open Access
Data from Relative Target Affinities of T-Cell–Dependent Bispecific Antibodies Determine Biodistribution in a Solid Tumor Mouse Model
2023Open Access
Supplementary Figure 1 from An Antimesothelin-Monomethyl Auristatin E Conjugate with Potent Antitumor Activity in Ovarian, Pancreatic, and Mesothelioma Models
2023Open Access
page 1 of 8Next →

Frequent Co-authors

Ryan J. Watts(16), Robert A. Lazarus(12), Raymond K. Tong(7), Hilda Solanoy(7), Charles Eigenbrot(7), Yanmei Lu(6), Do Jin Kim(6), Pascal E. Sanchez(6), Michelle E. Pizzo(6), Robert G. Thorne(6), Y. Joy Yu Zuchero(6), Yvonne Chen(5), Wilman Luk(5), Kapil Gadkar(5), Mihalis S. Kariolis(5), Cathal Mahon(5), Kirk R. Henne(5), Xiaocheng Chen(5), Meredith Calvert(5), Maria Hristopoulos(5)